Second-generation thiazolidinediones and hepatotoxicity

Annals of Pharmacotherapy

Volumn 38, Issue 9, 2004, Pages 1419-1423

  Marcy, Todd R ^a   Britton, Mark L ^a   Blevins, Steve M ^b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Hepatotoxicity; Pioglitazone; Rosiglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; LIVER ENZYME; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ADULT; AGED; ANOREXIA; ARTICLE; CASE REPORT; CONGESTIVE HEART FAILURE; FATIGUE; FEMALE; HUMAN; HYPERTENSION; LIVER TOXICITY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROBABILITY; PRURITUS; SYMPTOMATOLOGY; URINE LEVEL;

ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; HEPATITIS, TOXIC; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; LIVER FUNCTION TESTS; THIAZOLIDINEDIONES;

EID: 4143052336     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E072     Document Type: Article

References (21)

1. Scheen AJ. Thiazolidinediones and liver toxicity. Diabetes Metab 2001;27:305-13.
2. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000;132:118-21.
3. Al-Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone: a case report. Ann Intern Med 2000; 132:121-4.
4. Dhawan M, Agrawal R, Ravi J, Gulati S, Silverman J, Nathan G, et al. Rosiglitazone-induced granulomatous hepatitis. J Clin Gastroenterol 2002;34:582-4.
5. Ravinuthala RS, Nori U. Rosiglitazone toxicity (letter). Ann Intern Med 2000;133:658.
6. Gouda HE, Khan A, Schwartz J, Cohen RI. Liver failure in a patient treated with long-term rosiglitazone therapy. Am J Med 2001;111:584-5.
7. Bonkovsky HL, Azar R, Bird S, Szabo G, Banner B. Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Dig Dis Sci 2002;7:1632-7.
8. Maeda K. Hepatocellular injury in a patient receiving pioglitazone (letter). Ann Intern Med 2001;135:306.
9. Pinto AG, Cummings OW, Chalasani N. Severe but reversible cholestatic liver injury after pioglitazone therapy (letter). Ann Intern Med 2002; 137:857.
10. Chase MP, Yarze JC. Pioglitazone-associated fulminant hepatic failure (letter). Am J Gastroenterol 2002;97:502-3.
11. Nagasaka S, Abe T, Kawakami A, Kusaka I, Nakamura T, Ishikawa S, et al. Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success. Diabetic Med 2002;19:344-8.
12. May LD, Lefkowitch JH, Kram MT, Rubin DE. Mixed hepatocellular- cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002; 136:449-52.
13. Lumpkin MM. Troglitazone presentation to advisory committee May 19, 2000. Center for Drug Evaluation and Research/Food and Drug Administration. www.fda.gov/ohrms/dockets/ac/00/slides/3615sla/ (accessed 2004 Jan 12).
14. Holland EG, Young LY. Interpretation of clinical laboratory tests. In: Koda-Kimble MA, Young LY, eds. Applied therapeutics: the clinical use of drugs. 7th ed. Baltimore: Lippincott Williams & Wilkins, 2001:2-1-22.
15. Package insert. Avandia (rosiglitazone maleate). Triangle Park, NC: GlaxoSmithKline, May 2004.
16. Package insert. Actos (pioglitazone hydrochloride). Lincolnshire, IL: Takeda Pharmaceuticals America, December 2003.
17. Freid J, Everitt D, Boscia J. Rosiglitazone and hepatic failure (letter). Ann Intern Med 2000;132:64.
18. Isley WL, Oki JC. Rosiglitazone and liver failure (letter). Ann Intern Med 2000;133:393.
19. Gurakar A, Caraceni P, Fagiuoli S, Van Thiel DH. Andogenic/anabolic steroid-induced intrahepatic cholestasis: a review with four additional case reports. J Okla State Med Assoc 1994;87:399-404.
20. Package insert. Androgel (testosterone gel). Marietta, GA: Unimed Pharmaceuticals, November 2002.
21. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.